Advesya, a French/Swiss clinical-stage biotech company founded in 2020, is transforming the fight against cancer and autoimmune diseases. Building on years of academic research, advesya’s innovative work targets IL-1RAP, a unique antigen, which is upregulated in various cancers and autoimmune conditions.
Interleukin-1 receptor associated protein (IL-1RAP/IL-1R3) serves as a crucial point of convergence for IL-1-related cytokines. It primarily resides on the plasma membrane, where it functions as an essential co-receptor for IL-1R signal transduction. Additionally, IL-1RAP interacts with ST2 (IL-33R) and the IL-36 receptor. Notably, it is the sole shared node among the receptor complexes of IL-1 family of cytokines.
Given the strong association of IL-1-related cytokines with chronic inflammation, cancer, and autoimmune diseases, the upregulation of IL-1RAP and the activation of the pathway in several indications present a significant therapeutic opportunity, particularly since it is poorly expressed in healthy tissue.
Paris, France – Advesya, a company dedicated to developing novel therapies targeting IL-1RAP, announced that it will present two posters at the 66th American Society of Hematology (ASH) Annual Meeting, to be held in San Diego, California, from December 7 to 10, 2024. First Poster Presentation: Our collaborators at ALFA [...]
ADV-101: A Topoisomerase I Inhibitor ADC Targeting IL-1RAP Demonstrates Promising Efficacy in Preclinical Esophageal Cancer Models With an estimated 604,000 new cases diagnosed worldwide in 2020, Oesophageal cancer ranks as the seventh most common cancer globally and remains a challenging malignancy with poor prognosis. Chronic inflammation, driven by IL-1-related cytokines, [...]
© 2024 advesya | All rights reserved
